There are additional areas of improvement for Medicare accountable care organizations (ACOs) beyond what was proposed in the Pathways to Success regulation, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs (NAACOS).
Note: Since this video was filmed, CMS has finalized its overhaul of the Medicare Shared Savings Progam. Read more about the final rule.
There are additional areas of improvement for Medicare accountable care organizations (ACOs) beyond what was proposed in the Pathways to Success regulation, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs (NAACOS).
Transcript
What additional areas of improvement in MSSP would NAACOS like to see?
I think there is a lot of improvement that we can make in the program. I think that we are seeing improvements in this proposed Pathways to Success regulation. Some of those include the increased predictability and stability through longer agreement periods. I think we’d like to see more predictability and stability in relation to things like benchmarking, as well.
Also, as we look at the ACO program in comparison with other Medicare programs, we’d like to see more of an even playing field. For example, in Medicare Advantage, risk adjustment plays a much bigger role. We’d like to see ACOs get some of the same benefits of risk adjustment that we see under Medicare Advantage. We also would lie to see more flexibility for ACOs in relation to how they progress through the program and rather than have a one-size-fits-all methodology for some of these things, provide a little more flexibility.
We’d also like to see more control for ACOs in terms of exactly who’s in the ACO and who is not in the ACO. And increased beneficiary engagement, so that ACOs that are accountable for the cost and quality of beneficiary care can make sure that beneficiaries are going to the right providers in their community while at the same time kind of maintaining patient choice.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More